SYNTHOS RESEARCH

Emerson Electric EMR

Industrials · Industrial - Machinery · Synthos Deep Dive · 2026-08-04

$155.20
Hold

The Overview

Emerson sells the machinery that runs factories, refineries and power plants — the valves that control flow, the instruments that measure it, and the software that decides what to do. Over the last few years it also bought two software companies: AspenTech, which optimises industrial processes, and National Instruments, which makes test equipment.

It reported results this morning and they were good, without qualification. Sales grew 7%. New orders — the thing that tells you about next year rather than last quarter — grew 7%. Profit margins widened. Cash generation rose 36%. And the company raised its forecast for the year, which almost none of the companies in this research batch has done.

The market noticed. The shares rose 2.6% today and are now 1.7% below their highest price of the past year, having risen 17% in three months. The technical indicators say the stock is more stretched than any other name we looked at this week.

So the question is not whether Emerson is a good business — it plainly is — but what is left in the price. You pay about 22 times what analysts expect it to earn in the year to September 2027, for a company they expect to grow profits about 11% a year. The average analyst thinks the shares are worth $162, which is 2% above where they closed.

One accounting point worth knowing. Emerson reports two profit numbers: a statutory one of about $4.89 a share this year, and an "adjusted" one of about $6.55. The $1.66 difference is 84% amortisation of the intangible assets created when it bought those software companies. That charge does not go away for many years, and every valuation you read — including the multiples above — uses the higher number.

We think the shares are worth about $168 against $159. Nine dollars, on a company that has just reported and just risen. That is not enough.


Putting a number on it: our fair-value estimate is $168 against a current price of $155.20 — real upside if our numbers are right.

Our summary metrics

Downside Risk (lower = safer)5/10Moderate

"Rated 5. The operating business is strong and the balance sheet carries the cost of two large acquisitions. Supports: adjusted segment EBITA margin of 28.5%, up 140 basis points year on year; pretax margin of 18.8%, up 270 basis points; free cash flow of $1,323 million in a single quarter, up 36%, with full-year guidance of approximately $3.6 billion; net-debt-to-EBITDA of 2.39x; and a fiscal 2026 outlook that management raised rather than trimmed. Against that: goodwill of $18,193 million plus intangibles of $9,458 million is $27,651 million against total assets of $41,964 million — 65.9% — and against stockholders' equity of $20,282 million, so TANGIBLE BOOK VALUE PER SHARE IS MINUS $12.10. Total debt is $13,759 million against $1,544 million of cash for net debt of $12,215 million, and short-term debt of $4,797 million is more than three times the cash balance, so the company runs on commercial paper — which is why the February 2026 replacement of its 364-day backup facility matters, and why the SIZE of that replacement matters more: the new facility is $2 billion against the $3 billion it replaced, a one-third reduction in committed backup liquidity. The current ratio is 0.868 and working capital is negative $1,403 million. Amortisation of intangibles is guided at approximately $1.39 per share for fiscal 2026, 84% of the entire GAAP-to-adjusted bridge and roughly 21% of adjusted earnings, and it is a permanent consequence of the acquisitive model rather than a one-off. The chief executive's own quarterly commentary names the live exposure: the conflict in the Middle East remains fluid. And both the chief executive and the chief operating officer sold stock in the six months before this print, at $142.32 and $141.22 respectively."

Growth Quality6/10High

"Rated 6 — accelerating, and the acceleration is order-led, which is the right kind. The June 2026 quarter delivered net sales of $4,873M against $4,553M, up 7% reported and 6% on an underlying basis, with UNDERLYING ORDERS UP 7% — and orders lead sales in a capital-equipment business, so that is a forward statement. The business-unit detail is where the growth actually is: Test and Measurement, the former National Instruments business, grew 23% in the quarter and 18% over nine months; Control Systems and Software grew 7% in the quarter after only 3% over nine months, i.e. it accelerated sharply; Final Control grew 4% and 4%; Intelligent Devices 6% and 4%. Annual revenue: $16,785M (FY2020), $12,932M (FY2021), $13,804M (FY2022), $15,165M (FY2023), $17,492M (FY2024), $18,016M (FY2025) — note the FY2021 discontinuity, which is the Copeland climate business moving to discontinued operations, so the series is not comparable across that break. Management raised fiscal 2026 guidance to approximately 5% net sales growth, approximately 3.5% underlying, adjusted EPS of approximately $6.55 and free cash flow of approximately $3.6 billion. Consensus wants EPS of $6.506 in FY2026 (16 analysts), $7.196 in FY2027 (18) and $8.009 in FY2028 (7) — 8.4%, 10.6%, 11.3%. A 6 rather than higher because full-year underlying growth of approximately 3.5% is the honest rate and the 6-7% quarter is the good end of it; a 6 rather than lower because orders lead sales and orders are running ahead."

Exponential Potential4/10Moderate

"Rated 4. Emerson describes itself in its own release as a global automation leader engineering the autonomous future, and unlike most such phrasing there is something behind it. The company owns AspenTech, the industrial process-optimisation software business it took full control of, and National Instruments, now reported as Test and Measurement and growing 23% in the June quarter — the fastest line in the company. Control Systems and Software grew 7% in the quarter against 3% over nine months, and the chief executive attributes the 7% underlying order growth to being led by Software and Systems. That is a genuine mix shift from valves and instruments toward software and data, and software attached to an installed base of process-control hardware is a materially better business than the hardware. What holds this at 4: the mix shift is being bought rather than built — AspenTech and National Instruments cost roughly $13 billion between them across FY2022 and FY2024 and produced the $27.7 billion of goodwill and intangibles now carried against $20.3 billion of equity — and the underlying business remains valves, actuators, measurement devices and control systems sold into capital projects whose cycle Emerson does not control. The knowledge base's only thematically adjacent claims describe China targeting industrial automation for domestic self-sufficiency, which is a long-run competitive negative rather than a positive. A 4: a real and deliberate mix shift toward software, executed by acquisition, on top of a cyclical hardware base."

Fair value$168 $130–$205
What does “fair value” mean?

Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.

The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.

What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.

The Road Ahead

What we expect to matter in each window, and the evidence that would prove us wrong.

Short term 0-6 months

Neutral
Driver
"The most overbought entry in this batch, on the day of a guidance raise. Emerson closed 2026-08-04 at $158.88, UP 2.60%, having reported that morning a quarter with underlying orders up 7%, underlying sales up 6%, adjusted segment EBITA margin up 140 basis points to 28.5%, adjusted EPS up 13% to $1.71 and free cash flow up 36% to $1,323 million — with full-year guidance raised to approximately $6.55 of adjusted EPS and approximately $3.6 billion of free cash flow. The market's response has taken the stock to an RSI of 77.8, the highest in this batch and the only reading above 70; MACD is +3.52; the price is 11.3% above a 50-day moving average of $142.81 and 13.6% above a 200-day average of $139.85, and sits 1.7% below the 52-week high of $161.69. Three-month return is +17.3% against SPY's +7.6%, though twelve-month is +12.1% against SPY's +24.3%. The street's consensus target of $162.40 implies 2.2% of upside and the median $168 implies 5.7%. There is nothing wrong with this company and there is nothing left in the price for the next six months."
What we’re watching
"The fiscal fourth quarter, reporting in November, against management's guidance of approximately 5% net sales growth, approximately 5% underlying growth and approximately $1.85 of adjusted EPS. Within it: UNDERLYING ORDERS, which ran +7% in the June quarter and are the leading indicator for a capital-equipment business — this is the single number that matters and it is the one to watch first; adjusted segment EBITA margin against the 28.5% just delivered; whether Test and Measurement holds anything like its 23% quarterly growth; whether Control Systems and Software sustains the acceleration from 3% over nine months to 7% in the quarter; and the free-cash-flow run rate against the approximately $3.6 billion full-year guide, of which $1,323 million came in the June quarter alone. Also watch the capital-allocation pivot management described — approximately $1 billion of buyback and $1.2 billion of dividends in fiscal 2026 — against $1,243 million of repurchase in FY2025."
Confidence
Medium

Medium term 6-24 months

Tailwind
Driver
"The medium-term case is a mix shift toward software on top of a recovering automation cycle, and both halves are currently visible. Underlying orders grew 7% in the June quarter, led by Software and Systems per management; Control Systems and Software revenue accelerated from +3% over nine months to +7% in the quarter; Test and Measurement grew 23%. Adjusted segment EBITA margin reached 28.5%, up 140 basis points, and management raised full-year guidance rather than trimming it — the only guidance raise in this batch. Consensus wants adjusted EPS of $7.196 in FY2027 and $8.009 in FY2028, 10.6% and 11.3% growth, against underlying sales growth guided at approximately 3.5% for FY2026 — so the earnings algorithm is roughly one-third volume, one-third margin and one-third capital return, which is a durable combination for an industrial. Free cash flow of approximately $3.6 billion against an $88.99 billion market capitalisation is a 4.05% yield, and management has explicitly pivoted capital allocation toward returning it. Against that: full-year underlying growth of 3.5% is the honest organic rate, leverage at 2.39x with negative tangible book value limits the acquisitive lever that produced the software mix in the first place, and the intangible amortisation running at approximately $1.39 per share is a permanent 21% haircut to adjusted earnings."
What we’re watching
"Whether the order acceleration is a cycle or a step change. Underlying orders +7% in a quarter, with full-year underlying sales guided at approximately 3.5%, is a widening gap between what has been ordered and what has been shipped — favourable if it converts, and a warning if orders decelerate first. Watch: the underlying order rate quarter by quarter; the Control Systems and Software line, which is the software mix shift in numerical form; whether Test and Measurement's 23% is a rebound off a weak base (it was DOWN in the prior-year nine-month comparison, at $1,077M) or genuine share gain; the net-debt-to-EBITDA ratio against 2.39x, given that the company just reduced its committed backup facility from $3 billion to $2 billion; the tariff line, since fiscal 2026 guidance contains an IEEPA tariff refund of approximately $0.11 per share that will not repeat; and the Middle East exposure the chief executive names as fluid."
Confidence
Medium

Long term 2+ years

Tailwind
Driver
"Long-run Emerson occupies a defensible position: process automation is a business where the installed base is the moat, because replacing a plant's control system is a shutdown-level decision that owners avoid for decades. On top of that installed base Emerson has bought two software franchises — AspenTech in process optimisation and National Instruments in test and measurement — and the June quarter shows the mix shifting, with Software and Systems leading order growth and Test and Measurement growing 23%. Software attached to installed hardware is the best economic position in industrials and Emerson is deliberately building it. The secular demand argument, which management makes and which is half-weighted here, is that growth verticals support sustained investment. Against it stand two long-run objections. The first is in the knowledge base, obliquely: the only thematically adjacent claims in the entire store describe China targeting industrial automation as a strategic emerging industry with domestic self-sufficiency in all core technology — which is a statement about a large customer becoming a competitor. The second is on the balance sheet: goodwill and intangibles of $27,651 million against $20,282 million of equity means the software mix has already consumed the acquisitive capacity that created it."
What we’re watching
"Whether the software mix keeps rising as a share of revenue and whether Emerson ever discloses it as such — the vendor segment block reports only two lines, Intelligent Devices and Software and Control, while the earnings release reports four business units, so the software share is visible in the release and invisible in the payload. Whether AspenTech, now wholly owned, grows faster than the hardware. Whether China's stated push for domestic self-sufficiency in industrial automation shows up as share loss in the Asia, Middle East and Africa region, which was $5,449M of $18,016M in FY2025. Whether leverage falls enough to permit another acquisition, or whether the negative tangible book value and 2.39x net debt close that option. Whether intangible amortisation of approximately $1.39 per share declines as the acquisition cohort ages. And chief executive Surendralal Lanca Karsanbhai's capital-allocation record, which now includes a stated pivot from acquisition to shareholder return."
Confidence
Medium

Exponential Potential

Exponential Potential4/10Moderate

"Rated 4. Emerson describes itself in its own release as a global automation leader engineering the autonomous future, and unlike most such phrasing there is something behind it. The company owns AspenTech, the industrial process-optimisation software business it took full control of, and National Instruments, now reported as Test and Measurement and growing 23% in the June quarter — the fastest line in the company. Control Systems and Software grew 7% in the quarter against 3% over nine months, and the chief executive attributes the 7% underlying order growth to being led by Software and Systems. That is a genuine mix shift from valves and instruments toward software and data, and software attached to an installed base of process-control hardware is a materially better business than the hardware. What holds this at 4: the mix shift is being bought rather than built — AspenTech and National Instruments cost roughly $13 billion between them across FY2022 and FY2024 and produced the $27.7 billion of goodwill and intangibles now carried against $20.3 billion of equity — and the underlying business remains valves, actuators, measurement devices and control systems sold into capital projects whose cycle Emerson does not control. The knowledge base's only thematically adjacent claims describe China targeting industrial automation for domestic self-sufficiency, which is a long-run competitive negative rather than a positive. A 4: a real and deliberate mix shift toward software, executed by acquisition, on top of a cyclical hardware base."

What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.

Deeper analysis

Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.

Check our number Market-implied growth ≈ 16%/yr This isn’t how we calculate fair value — it’s public math you can verify yourself. To justify today’s $155, earnings would have to compound roughly 16% a year for 10 years (9% discount rate). Analysts forecast ~12%/yr, so the market is pricing in MORE than what the Street expects.

> ## ⚠ RESULTS AND A GUIDANCE RAISE RELEASED THE MORNING OF THIS DIVE

>

> Emerson issued its fiscal third-quarter release on 2026-08-04"Emerson Reports Third Quarter 2026 Results; Raises 2026 Outlook"and filed its 10-Q the same day. Both are in this archive with tables preserved, so every figure below is filing-verified through 2026-06-30.

>

> The quarter: net sales $4,873M (+7%), underlying sales +6%, UNDERLYING ORDERS +7%, pretax margin 18.8% (+270bp), adjusted segment EBITA margin 28.5% (+140bp), GAAP EPS $1.28 (+24%), adjusted EPS $1.71 (+13%), operating cash flow $1,425M (+34%), free cash flow $1,323M (+36%).

>

> Guidance RAISED: fiscal 2026 adjusted EPS to approximately $6.55, free cash flow to approximately $3.6 billion.

>

> The shares closed +2.60% at an RSI of 77.8 — the only reading above 70 in this batch. The verdict below is set with that as a direct input.


Reference table

Street consensus$162.40 (+2.2%) · median $168 (+5.7%) · high $185 (+16.4%) · low $144 (−9.4%) · 0 strong buy / 22 buy / 16 hold / 3 sell across 41 analysts · vendor consensus label Buy
Valuation24.4x FY2026E adjusted ($6.506) · 22.1x FY2027E ($7.196) · 19.8x FY2028E ($8.009) · 36.4x trailing · 32.5x guided FY2026 GAAP EPS of ~$4.89 · EV/EBITDA 19.7x · P/tangible book NOT MEANINGFUL — tangible book is MINUS $12.10/share
The June quarter — filing-verifiedNet sales $4,873M vs $4,553M (+7%) · underlying sales +6% · UNDERLYING ORDERS +7% · pretax earnings $916M vs $734M, margin 18.8% vs 16.1% (+270bp) · adjusted segment EBITA $1,387M vs $1,232M, margin 28.5% vs 27.1% (+140bp) · GAAP EPS $1.28 vs $1.03 (+24%) · adjusted EPS $1.71 vs $1.52 (+13%) · free cash flow $1,323M vs $970M (+36%)
Guidance RAISEDFY2026: net sales growth ~5%, underlying ~3.5%, adjusted EPS ~$6.55, GAAP EPS ~$4.89, operating cash flow ~$4.1B, free cash flow ~$3.6B (a 4.05% yield). Q4: sales ~5%, underlying ~5%, adjusted EPS ~$1.85
The GAAP-to-adjusted bridge, and it is mostly permanentGuided FY2026: GAAP ~$4.89 + intangible amortisation ~$1.39 + restructuring ~$0.24 + acquisition fees ~$0.09 + discrete taxes ~$0.05 − IEEPA tariff refunds ~($0.11) = adjusted ~$6.55. Amortisation is 84% of the bridge and roughly 21% of adjusted earnings
Where the growth isQ3 business units, reported / underlying: Test & Measurement $445M, +23%/+23% · Control Systems & Software $1,199M, +7%/+7% · Intelligent Devices $2,677M, +6%/+5% · Final Control $1,586M, +4%/+3%
Capital allocation pivot"As we pivot capital allocation to returning cash to shareholders, the 2026 outlook assumes returning ~$2.2B through ~$1B share repurchases and ~$1.2B of dividends." Quarterly dividend declared at $0.555
Balance sheetTotal debt $13,759M against $1,544M of cash → net debt $12,215M, 2.39x EBITDA · short-term debt of $4,797M is 3.1x the cash balance · goodwill + intangibles $27,651M = 65.9% of assets against $20,282M of equity · tangible book value per share MINUS $12.10 · current ratio 0.868
Corporate action ABSENT from the payloadA $2 billion 364-day credit facility entered 2026-02-10, replacing a $3 billion facility that expired — a one-third reduction in committed backup liquidity for a company funding itself with $4,797M of short-term debt
TechnicalsRSI 77.8 — the only reading above 70 in this batch; MACD +3.52; +11.3% above the 50-DMA ($142.81), +13.6% above the 200-DMA ($139.85); −1.7% from the 52-week high of $161.69; 3-month +17.3% vs SPY +7.6%; 12-month +12.1% vs SPY +24.3%
Knowledge baseEMPTY. 140 raw hits, 3 case-sensitive survivors, and the only entity match is EMERSON COLLECTIVE — Laurene Powell Jobs's philanthropic LLC. A clean homograph collision

What the experts actually said

No independent expert claims in the Synthos knowledge base yet for EMR — this dive is fundamentals- and technicals-driven, not panel-driven.

Price & moving averages 12 months · 50 & 200-day averages · 52-week range

120132144156168Aug '25Nov '25Jan '26Apr '26Jun '26Aug '2652w hi $164Price 15550-DMA 149200-DMA 14252w lo $123

Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.

Data summary: last close $155.18, 4% above the 50-day average ($149), 9% above the 200-day average ($142) — an uptrend. 6% below the 52-week high of $164, 26% above the 52-week low of $123.

Bollinger Bands 20-day average ± 2 standard deviations

116131145160174Aug '25Nov '25Jan '26Apr '26Jun '26Aug '2620-day avg 159Price 155

The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.

Data summary: price $155.18 is currently inside the band (band $153–$165).

RSI (14) momentum gauge · 0–100

705030Aug '25Nov '25Jan '26Apr '26Jun '26Aug '26RSI 50.4

Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 50.

MACD 12 / 26 / 9 · trend & momentum

0Aug '25Nov '25Jan '26Apr '26Jun '26Aug '26signal 3.2MACD 2.1

The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.

Data summary: MACD is currently below its signal line by 1.08, negative momentum.

Relative performance vs S&P 500 & its sector (XLI (sector)), set to 100 a year ago

8998107116125Aug '25Nov '25Jan '26Apr '26Jun '26Aug '26S&P 500 119XLI (sector) 115EMR 115

Solid = EMR · dashed = S&P 500 · dotted = XLI (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.

Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate

07132027$15BFY23EPS $4$17BFY24EPS $5$18BFY25EPS $6$19BFY26EEPS $7$20BFY27EEPS $7$21BFY28EEPS $8$22BFY29EEPS $9$24BFY30EEPS $10

Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.

Key stats an RIA wants

Price$155.20
Market cap$87B
P/E trailing34×
P/E FY26E / FY27E24× / 21×
EV / Sales5.3×
EV / EBITDA19.2×
Gross margin53.2%
Net margin13.8%
Dividend yield1.43%
Beta1.235
52-wk range$123 – $164
RSI(14)44
50 / 200-DMA$149 / $142
12-mo return+16% (SPY +19%)
Street target$165 ($135–$186)
Analyst grades23 Buy · 16 Hold · 3 Sell
FMP ratingB
Next earnings2026-11 (fiscal fourth-quarter and full-year 2026 results, date not yet in the vendor calendar; management guides Q4 net sales growth of approximately 5%, underlying growth of approximately 5% and adjusted EPS of approximately $1.85). Third-quarter results were released on the MORNING OF 2026-08-04, the day this dive is struck, and beat consensus adjusted EPS by 1.8% ($1.71 against $1.68) with full-year guidance RAISED.

1. The June quarter, and the guidance raise

All figures from Exhibit 99.1 to the 8-K filed 2026-08-04, tables preserved. Emerson's fiscal year ends 30 September, so this is fiscal third-quarter 2026.

($M, except per share)2026 Q32025 Q3change
Underlying orders+7%
Net sales$4,873$4,553+7%
Underlying sales+6%
Pretax earnings$916$734+24.8%
Pretax margin18.8%16.1%+270 bp
Adjusted segment EBITA$1,387$1,232+12.6%
Adjusted segment EBITA margin28.5%27.1%+140 bp
GAAP EPS$1.28$1.03+24%
Adjusted EPS$1.71$1.52+13%
Operating cash flow$1,425$1,062+34%
Free cash flow$1,323$970+36%

Management's own words, quoted in full because the framing matters and is half-weighted:

> "Emerson had an outstanding third quarter with sales, margin expansion, earnings and cash flow all exceeding expectations... Demand was robust, with underlying orders up 7%, led by Software & Systems and broad-based growth in North America and Asia. The conflict in the Middle East remains fluid, and I am proud of our team's ability to deliver results and support our customers around the world."

> "We are raising our full year guidance, reflecting our strong third quarter performance and healthy demand. Secular tailwinds continue to support sustained investment in our growth verticals..."

Note that the chief executive names the Middle East conflict in a results statement — the third name in this batch to do so, after Marathon Petroleum (whose refining margin doubled because of it) and Marriott (whose international RevPAR fell 0.5% because of it).

The business units — this is where the growth is

Business unitQ3 2026Q3 2025reportedunderlying9M 20269M 20259M reported
Test & Measurement$445M$360M+23%+23%$1,268M$1,077M+18%
Control Systems & Software$1,199M$1,120M+7%+7%$3,332M$3,235M+3%
Intelligent Devices$2,677M$2,535M+6%+5%$7,580M$7,301M+4%
Final Control$1,586M$1,522M+4%+3%$4,469M$4,315M+4%

Two things to read out of that.

Test and Measurement — the former National Instruments business — grew 23% in the quarter and 18% over nine months. It is the smallest unit at $445M a quarter and by far the fastest. Whether that is genuine share gain or a rebound off a weak base is the medium-term question, and this archive cannot settle it.

Control Systems and Software accelerated sharply: +3% over nine months and +7% in the quarter. Combined with the chief executive's attribution of the 7% order growth to "Software & Systems", that is the software mix shift showing up in the numbers for the first time in this file.

The guidance, raised

FY2026 guidance (approximate)Q4Full year
Net sales growth~5%~5%
Underlying sales growth~5%~3.5%
GAAP earnings per share~$1.45~$4.89
plus amortisation of intangibles~$0.34~$1.39
plus restructuring and related~$0.03~$0.24
plus acquisition/divestiture fees~$0.01~$0.09
plus discrete taxes~$0.02~$0.05
less IEEPA tariff refunds~($0.11)
Adjusted earnings per share~$1.85~$6.55
Operating cash flow~$4.1B
Free cash flow~$3.6B

Three observations on the bridge, and they matter for every multiple in this dive.

The adjustment is $1.66 per share, 34% of guided GAAP earnings, and 84% of it is intangible amortisation. Emerson carries $9,458 million of intangibles from AspenTech, National Instruments and earlier deals. That amortisation runs for years and is not a one-off in any meaningful sense. On guided GAAP earnings of ~$4.89 the stock is 32.5x; on guided adjusted earnings of ~$6.55 it is 24.3x. Both are published here and consensus uses the adjusted basis.

There is a tariff refund in the guidance. "IEEPA tariff refunds ~($0.11)" is a negative adjustment, i.e. a gain being excluded from adjusted earnings — approximately $62 million on 560 million shares. It will not repeat.

The company guides full-year underlying sales growth at approximately 3.5% while the June quarter delivered 6% and Q4 is guided at approximately 5%. The arithmetic implies the first half was materially weaker, which the nine-month business-unit growth rates confirm (+3%, +4%, +4%). The 6-7% quarter is the good end of the year, not the run rate.

2. Balance sheet, cash flow and the facility that shrank

($M)2025-09-302024-09-30
Cash and equivalents$1,544$3,588
Inventory$2,213$2,180
Total current assets$8,583$10,192
Property, plant & equipment, net$3,508
Goodwill$18,193
Intangible assets$9,458
Total assets$41,964
Short-term debt$4,797
Long-term debt$8,319
Capital lease obligations$643
Total debt$13,759
Net debt$12,215
Total current liabilities$9,797
Total stockholders' equity$20,282
Minority interest$16$5,909
Tangible book value per shareMINUS $12.10
Net debt / EBITDA2.386x
Current ratio0.868

Three things.

Goodwill and intangibles of $27,651M are 65.9% of total assets and 136% of equity. Tangible book value per share is MINUS $12.10, so priceToBookRatioTTM of 4.39x is on a book value that contains no tangible assets net of liabilities. returnOnEquityTTM is not in ratios_ttm and is not in km_ttm either on this name — the block is truncated, so no return-on-equity figure is available from the payload at all. We use returnOnInvestedCapitalTTM and note the gap.

The minority interest collapsed from $5,909M to $16M between the two balance dates. That is the AspenTech buy-in: Emerson moved from majority to full ownership, extinguishing the noncontrolling interest. cf_a reports acquisitionsNet of ZERO for FY2025, which is technically correct — purchasing the remaining stake in an already-consolidated subsidiary is an equity transaction recorded in financing, not an acquisition — but it means the payload contains no trace of a roughly $6 billion transaction. Anyone reading cf_a alone would conclude Emerson made no acquisitions in fiscal 2025.

The company funds itself short. Short-term debt of $4,797M is 3.1x the $1,544M cash balance, and the current ratio is 0.868 with negative working capital of $1,403M. That is normal for a large investment-grade industrial running a commercial-paper programme — and it makes the backup facility important.

The corporate action the payload never saw

From Item 2.03 of the 8-K filed 2026-02-13, verbatim:

> "On February 10, 2026, Emerson Electric Co.... entered into a $2 billion 364-Day Credit Agreement... The 364-Day Credit Facility expires on February 9, 2027. There are no outstanding loans or letters of credit under the 364 Day Credit Facility. The Company has not incurred any borrowings under this or prior similar facilities, and has no current intention to do so. The 364-Day Credit Facility supports general corporate purposes, including as a liquidity back-up for the Company's commercial paper borrowings."

> "The facility replaces the Company's $3 billion 364-Day Credit Agreement entered into on February 11, 2025, which expired by its terms."

A $2 billion facility replacing a $3 billion facility is a one-third reduction in committed backup liquidity, for a company with $4,797 million of short-term debt against $1,544 million of cash. Emerson has never drawn on it and says it has no intention to, and the reduction most plausibly reflects a smaller commercial-paper programme after the AspenTech buy-in was financed — but it is a material financing fact and it appears nowhere in the vendor payload.

Cash flow

Fiscal yearOCFCapexFCFD&Acapex/D&Acapex/revenue
FY2022$2,922M−$531M$2,391M$842M0.63x3.85%
FY2023$637M−$363M$274M$1,051M0.35x2.39%
FY2024$3,332M−$419M$2,913M$1,689M0.25x2.40%
FY2025$3,098M−$431M$2,667M$1,518M0.28x2.39%
FY2026 guidance~$4,100M~$3,600M

Free cash flow is computed by subtraction and the arithmetic is correct in all four years. capexToDepreciationTTM of 0.28x is well below 1.0 — the corruption signature — but it is explained rather than suspicious: D&A of $1,518M includes intangible amortisation guided at approximately $1.39 per share, roughly $780 million a year, so real depreciation is nearer $740 million against $431 million of capex, a ratio of about 0.58x. That is still low, and it is the correct reading of an asset-light-ish industrial that has bought its growth: the depreciation line is dominated by purchase accounting, not by plant. The FY2023 outlier — operating cash flow of $637M — is the Copeland divestiture year and is not comparable.

The company's own guided free cash flow of ~$3.6 billion against an $88.99 billion market capitalisation is a 4.05% yield, materially above the vendor's freeCashFlowYieldTTM derivation, because the guidance is forward and the trailing figure includes the weaker first half. Both are stated.

3. Segments and geography — both vendor blocks tie

seg_prod FY2025: Intelligent Devices $12,400M + Software and Control $5,691M = $18,091M against inc_a revenue of $18,016M100.4%. Ties. But note the block reports TWO lines while the earnings release reports FOUR business units, so the Test and Measurement and Control Systems and Software detail that carries the growth story is invisible in the payload and available only from the release.

seg_geo FY2025: Americas $9,214M (51.1%) + Asia, Middle East & Africa $5,449M (30.2%) + Europe $3,428M (19.0%) = $18,091M against $18,016M — 100.4%. Ties, correctly labelled, three genuine regions, no aggregate double-counting.

Both blocks clean — recorded as a finding, and notable because four of the twelve names in this batch have a broken geography block (UPS at 72.8%, MRSH at 162.8%, WM with the US line absent, MAR with the US line absent).

What the geography shows: Asia, Middle East and Africa is 30.2% of revenue and grew 2.5% in FY2025, Americas 51.1% and grew 4.7%, Europe 19.0% and FELL 0.5%. The chief executive's reference to "broad-based growth in North America and Asia" in the June quarter is therefore an improvement on the annual pattern, and Europe is the region to watch.

4. Valuation — priced in or room?

At $158.88 (market cap $88.99B, ~560.1M shares implied):

TrailingFY2026E (Sep)FY2027EFY2028EFY2029E
Consensus adjusted EPS$4.360$6.506 (16)$7.196 (18)$8.009 (7)$9.122 (2)
Company guidance~$6.55
EPS range$6.446–$6.556$6.934–$7.357$7.179–$8.829
EPS growth+8.4% (vs FY2025E $6.001)+10.6%+11.3%+13.9%
P/E on adjusted24.4x22.1x19.8x17.4x
P/E on guided GAAP (~$4.89)36.4x32.5x
Consensus revenue$18,316M (TTM)$18,822M (19)$19,853M (21)$20,881M (15)$22,431M (10)
Revenue growth+4.5%+5.5%+5.2%+7.4%
EV/EBITDA19.7x
Free-cash-flow yield (on guided ~$3.6B)4.05%
Dividend yield1.38%

Estimate coverage is good through FY2028 — 16, 18 and 7 analysts on EPS — and collapses to 2 at FY2029. The FY2029 and FY2030 rows are excluded from every conclusion. The FY2027 EPS range is $6.934 to $7.357, a 6.1% spread — the narrowest in this batch alongside MRSH, which is what a well-modelled industrial with company guidance looks like.

The guidance calibration is worth recording: management's ~$6.55 for FY2026 sits 0.7% ABOVE the consensus $6.506, and the FY2026 consensus range is only $6.446 to $6.556 — a 1.7% spread. The near year is effectively settled; everything in the valuation is about FY2027 and beyond.

est.ebitdaAvg and est.ebitAvg are REJECTED for TWO independent reasons. First, the fixed-ratio signature: ebitdaAvg is exactly 31.42% of revenueAvg and ebitAvg exactly 19.03% in every year FY2026 through FY2030. Second, and decisively: netIncomeAvg EXCEEDS ebitAvg in EVERY forward year — $3,657M against $3,581M (FY2026), $3,971M against $3,777M (FY2027), $4,329M against $3,973M (FY2028), $5,170M against $4,267M (FY2029), $5,707M against $4,532M (FY2030). Net income cannot exceed operating income for a company that pays interest of $387M and tax at 21.2%. This is the same impossibility class found on COF and, in a different form, on ABNB in this batch. All forward valuation uses epsAvg. Twentieth consecutive name.

Peer set is a market-capitalisation cohort with two genuine comparables. CMI, CTAS, HWM, ITW, JCI, NOC, PH, TDG, UPS, WM. Parker-Hannifin is the closest business comparable; Illinois Tool Works and Johnson Controls are adjacent. UPS and WM are in this same research batch and are not automation businesses. The payload carries no peer estimates, so no multiple comparison is computed.

4a. What today's price assumes (the inversion)

At $158.88 — 24.4x fiscal 2026 consensus, 22.1x fiscal 2027 — the price embeds:

4b. The return bridge (why the multiple moves)

Expected return over the next twelve months decomposes as: adjusted EPS growth (+10.6%, from FY2026E $6.506 to FY2027E $7.196) + multiple drift (MODEST EXPANSION; our base of $168 is 23.3x FY2027E against 22.1x today, +5.7%) + shareholder yield (approximately +2.5%: ~$1B of buyback and ~$1.2B of dividends against an $88.99B market capitalisation)+17% if the re-rating comes and roughly +13% if it does not.

Our base assumes a modest multiple expansion and names it as the fragile leg — and here it is more fragile than usual, because 22.1x is already at the upper end of the band this business has occupied. The argument for it: underlying orders +7%, a software mix shift showing in the numbers for the first time, the only guidance raise in this batch, a 4.05% guided free-cash-flow yield, and a stated pivot to capital return. The argument against it: full-year underlying growth guided at ~3.5%, RSI at 77.8, and a consensus price target 2.2% above the close.

If the multiple simply holds at 22.1x, fair value is roughly $159 — spot — and the return is 10.6% of earnings growth plus 2.5% of yield. That is the honest floor and it is why this is a Hold rather than anything warmer.

4c. Variant perception (where we differ, what would surprise)

Synthos fair values

All three anchors are multiples of the FY2027 consensus adjusted EPS distribution (mean $7.196, low $6.934, high $7.357, 18 analysts). The FY2029 row (2 analysts) and FY2030 row (5) are excluded from every conclusion.

Base is 5.7% above spot; asymmetry 1.59:1 (18.2% down, 29.0% up), plus a ~2.5% shareholder yield. A base case barely outside the Hold band, a payoff ratio well short of the 2:1 Tactical bar, and the most overbought entry in the batch. Hold.

5. Knowledge base — a textbook homograph collision, and an empty lane

Raw hits: 140. After a case-sensitive entity re-run: 3. Name-level claims on Emerson Electric: ZERO. Used: 0. Discarded: 140.

The sweep ran entity terms EMR, Emerson, Emerson Electric, AspenTech and AZPN, plus free text on Emerson Electric, AspenTech, industrial automation, emerson and automation, across the full distilled claim store.

The single entity-bearing survivor is the collision itself, and it is the cleanest example in this batch:

> 2022-12-15 · neutral · conviction 65 · horizon: thesis · entities: Chan-Zuckerberg Initiative, EMERSON COLLECTIVE · channel: dwarkesh

> "Tech wealth is shifting philanthropy from 501(c)(3) foundations to LLCs and donor-advised funds for flexibility to fund companies, nonprofits, and individuals."

Emerson Collective is the philanthropic limited liability company founded by Laurene Powell Jobs. It has no relationship whatsoever to Emerson Electric Co. A case-insensitive entity sweep on "Emerson" would have imported a claim about philanthropic vehicle structures into an industrial-automation dive at conviction 65 — and, exactly as the CEG / Constellation Software case demonstrated, it would have read as substantive because the claim itself is coherent and well-formed. This is the CEG / PWR / USB pattern and it is reported as one.

The two other case-sensitive survivors are free-text matches on "industrial automation" with EMPTY entity lists, and both are about China:

> 2025-06-19 · bullish · conviction 70 · horizon: thesis · entities: (none) · channel: dwarkesh

> "China's 'strategic emerging industries' target obvious winners — semiconductors, industrial automation, new materials — and it wants domestic self-sufficiency in all core tech including AI."

> 2025-05-29 · bullish · conviction 60 · horizon: fact · entities: China · channel: dwarkesh

> "Data centers being built in China at a very fast clip using existing command structure; industrial automation already advanced."

Note the direction. Both are tagged bullish — bullish on China's industrial policy — and for a Western automation vendor with 30.2% of revenue in Asia, the Middle East and Africa, a claim that China targets industrial automation for domestic self-sufficiency is a mild NEGATIVE. This is a milder version of the stance-tag problem caught on ABNB in this batch: the tag describes the theme, not the implication for any particular company. Neither claim names a company and neither is used in the conviction score; both are recorded because they are the only material in the store that touches this business at all.

The remaining 137 raw hits are noise on the word "automation" across 43 channels, dominated by artificial-intelligence discussion — cognitive_revolution (16), no_priors (10), all_in (8), lex_fridman (8) and thirty-nine others. None names an industrial company.

Conclusion. Breadth 0, claim count 0, net conviction NONE. The lane is EMPTY and is reported as empty rather than padded, consistent with the treatment of CSX, JCI and — in this batch — MRSH and WM. Conviction contributes exactly zero to this verdict.

Recorded alongside the insurance-brokerage and environmental-services findings elsewhere in this batch: the store has essentially no coverage of the diversified industrial sector either. Three of the twelve names in this batch have a genuinely empty lane, and all three are old-economy industrials or financials.

6. Data integrity — what we rejected and why

Seven findings.

1. est.ebitAvg is EXCEEDED BY est.netIncomeAvg in every forward year — arithmetically impossible. REJECTED. $3,657M against $3,581M (FY2026), $3,971M against $3,777M (FY2027), $4,329M against $3,973M (FY2028), $5,170M against $4,267M (FY2029), $5,707M against $4,532M (FY2030). Net income cannot exceed operating income for a company with $387M of interest expense and a 21.2% effective tax rate. Compounded by the fixed-ratio signature: ebitdaAvg is exactly 31.42% of revenueAvg and ebitAvg exactly 19.03% in all five forward years. All forward valuation uses epsAvg, which calibrates well — the FY2026 consensus of $6.506 sits 0.7% below management's own guidance of ~$6.55.

2. A ROUGHLY $6 BILLION TRANSACTION IS INVISIBLE IN cf_a. minorityInterest collapsed from $5,909M (2024-09-30) to $16M (2025-09-30) — the AspenTech buy-in from majority to full ownership — while cf_a reports acquisitionsNet of ZERO for FY2025. The zero is technically correct (purchasing the remaining stake in an already-consolidated subsidiary is a financing transaction, not an acquisition) and it is nonetheless misleading: a reader using cf_a alone would conclude Emerson made no acquisitions in fiscal 2025. The balance-sheet line is the only trace in the payload.

3. A CORPORATE ACTION IS ABSENT: the 364-day credit facility was REPLACED AND REDUCED. From the 8-K of 2026-02-13: a $2 billion 364-day facility entered 2026-02-10, expiring 2027-02-09, replacing a $3 billion facility that expired by its terms. A one-third reduction in committed backup liquidity for a company carrying $4,797M of short-term debt against $1,544M of cash. Never drawn, and the company says it has no intention to draw — but it appears nowhere in the payload.

4. capexToDepreciationTTM of 0.28x is below 1.0 — the corruption signature — and it is EXPLAINED, not corrupt. D&A of $1,518M includes intangible amortisation guided at approximately $1.39 per share, roughly $780 million a year, so real depreciation is nearer $740 million against $431 million of capex — a ratio of about 0.58x, which is low but normal for a company whose depreciation line is dominated by purchase accounting. Free cash flow is computed by subtraction and is correct in all four years. No correction is applied, and the company's own guided FY2026 free cash flow of ~$3.6 billion (a 4.05% yield) is used in preference to the trailing figure.

5. returnOnEquityTTM is ABSENT FROM BOTH km_ttm AND ratios_ttm on this name. On the previous nineteen names in this programme the field appeared in km_ttm and was missing from ratios_ttm; here the km_ttm block is truncated after investedCapitalTTM and the return ratios are missing entirely, so no return-on-equity, return-on-assets or return-on-invested-capital figure is available from the payload at all. This is a new variant of the recurring block asymmetry and it is recorded as such. No return-on-capital figure is published in this dive because none is available and none is estimated.

6. The vendor segment block reports TWO business lines where the company reports FOUR. seg_prod carries Intelligent Devices $12,400M and Software and Control $5,691M, summing to $18,091M against $18,016M of revenue — 100.4%, a clean tie — but the earnings release reports Final Control, Test & Measurement, Control Systems & Software and Intelligent Devices separately, and the growth story is entirely in the two lines the payload does not carry (Test & Measurement +23%, Control Systems & Software +7%). Not a defect; a resolution gap, and it means the software mix shift is invisible to anyone screening on the payload.

7. inc_a FY2023 netIncome of $13,219M against incomeBeforeTax of $2,903M is the Copeland divestiture gain and is not comparable to any other year. Similarly operatingCashFlow of $637M in FY2023 against $2,922M, $3,332M and $3,098M in the surrounding years. Both are correct and both would destroy any multi-year average. No comparison in this dive uses FY2023 net income, EPS or operating cash flow.

seg_geo — CHECKED AND CLEAN. Americas $9,214M + Asia, Middle East & Africa $5,449M + Europe $3,428M = $18,091M against $18,016M, 100.4% — correctly labelled, three genuine regions, no aggregate double-counting. Notable because four of the twelve names in this batch have a broken geography block.

Enterprise value — CHECKED, small residual, ACCEPTED. enterpriseValueTTM of $101,255M against a rebuild of market cap $88,989M + total debt $13,759M − cash $1,544M + minority interest $16M = $101,220M. A 0.03% residual — the tightest reconciliation in this batch. EV/EBITDA of 19.7x is used as reported.

Quote versus technical blocks. quote.yearHigh/yearLow report $165.15 / $122.64; tech.hi52/lo52 report $161.69 / $123.30. Differences of 2.1% and 0.5%. tech is used throughout. tech.max_dd_from_peak (−1.738%) is identical to tech.pct_from_hi.

Non-equity tripwire — checked and passed. Common stock, NYSE-listed, Missouri incorporation, Commission File Number 1-278. Price $158.88; beta 1.235; volume 3.94M shares (~$626M of turnover); 52-week band $123.30-$161.69, a 31% range. This is common equity.

7. Technicals, insiders and verdict

Technicals

Today's move. EMR closed UP 2.60% at $158.88 from $154.85, opening at $156.00 and trading $152.28 to $159.37 on 3.94M shares — closing within 0.3% of the day high. The results 8-K and the 10-Q were both filed 2026-08-04.

The honest read: this is the worst entry in the batch and the best quarter in the batch, and both facts are true at once. Buying at the 93rd percentile of the annual range, 11.3% above the 50-day average, at an RSI of 77.8, on the afternoon of the news, into a consensus target 2.2% away, is a decision made by the calendar rather than by arithmetic.

Insiders — two executive sales, both below today's price

The file contains a mixture of sales, gifts and tax withholdings. The two discretionary transactions are both sales by the two most senior executives.

Surendralal Lanca Karsanbhai — Director, President and Chief Executive Officer — sold 5,700 shares at $142.32 on 2026-03-10, retaining 281,393 (indirect). Ram R. Krishnan — Executive Vice President and Chief Operating Officer — sold 11,500 shares at $141.22 on 2026-06-01, retaining 159,639 (indirect), having earlier made two gifts totalling 6,680 and 53,366 shares on 2026-03-09. Michael H. Train, SVP and Chief Sustainability Officer, had 5,286 shares withheld for tax (F-InKind) at $131.61 on 2026-04-06.

The reading. Both discretionary transactions are sales, both by the top two executives, and both were executed 10-12% BELOW today's close. The amounts are small — approximately $811,000 and $1.62 million — and both retain large positions (281,393 and 159,639 shares), so these are routine diversification rather than a statement. There is not one open-market purchase in the file. The most useful thing about them is the calibration: the chief executive and chief operating officer were content to sell at $142 and $141 five and two months ago, and the stock is now $158.88.

Verdict

Hold.

Struck on the afternoon of a guidance raise, with the share-price reaction as a direct input.

The arithmetic. At $158.88 Emerson trades at 24.4x the fiscal 2026 consensus of $6.506 (against company guidance of ~$6.55) and 22.1x fiscal 2027's $7.196, for consensus growth of 10.6% — and at 32.5x guided fiscal 2026 GAAP earnings of ~$4.89. Our base fair value of $168 is 5.7% above spot, identical to the street's median, with 1.59:1 asymmetry ($130 bear, $205 bull) and a ~2.5% shareholder yield. The street's consensus target of $162.40 implies 2.2%.

What is genuinely excellent, and it is a lot. Underlying orders +7% — the correct leading indicator for a capital-equipment business — underlying sales +6%, pretax margin +270 basis points to 18.8%, adjusted segment EBITA margin +140 basis points to 28.5%, adjusted EPS +13%, free cash flow +36% to $1,323 million, and full-year guidance RAISED to ~$6.55 of adjusted earnings and ~$3.6 billion of free cash flow — a 4.05% yield. Test and Measurement grew 23% and Control Systems and Software accelerated from +3% over nine months to +7% in the quarter, which is the software mix shift appearing in the numbers for the first time. This is the only guidance raise in this batch, and both vendor segment blocks tie, and the enterprise-value reconciliation is the tightest in the twelve.

What keeps it at Hold.

First, the entry. RSI 77.8 — the only reading above 70 in this batch. 11.3% above the 50-day average. 93rd percentile of the annual range. Up 2.6% today and 17.3% in three months. A consensus target 2.2% above the close.

Second, the base case is 5.7% above spot and requires a multiple expansion from 22.1x, which is already at the upper end of the band this business has occupied. If the multiple holds, fair value is spot.

Third, full-year underlying growth is guided at approximately 3.5%, not 6%. The June quarter is the good end of the year; the nine-month business-unit rates are +2% to +4%.

Fourth, roughly 21% of "adjusted earnings" is excluded intangible amortisation of approximately $1.39 per share — 84% of the GAAP-to-adjusted bridge, and permanent. The market pays 22.1x on one basis and 32.5x on the other.

Fifth, the balance sheet has no tangible backing — goodwill and intangibles of $27,651M are 65.9% of assets, tangible book value per share is MINUS $12.10, short-term debt is 3.1x cash, and the backup facility was just reduced from $3 billion to $2 billion.

Sixth, the knowledge base is empty and the only entity match in 140 hits is a philanthropic LLC.

Pre-registered KILL criteria — what would take this to Avoid:

Pre-registered UPGRADE conditions — what would take this to Buy — Tactical:

Where EMR fits in the Synthos Framework Portfolio. No position today; a named limit at roughly $140. This is a high-quality automation franchise with a real and deliberate software mix shift, executing well, that has just told the market so and been paid for it. The disciplined action is to want it and to wait: a 1.5% starter at $140, scaling to 3% on a second consecutive quarter of 8%+ underlying orders. Both the chief executive and the chief operating officer were willing sellers at $141-142 within the last five months; paying $158.88 the afternoon the news broke is the opposite side of that trade. Logged as a tracked Synthos call (Hold) as of 2026-08-04 at $158.88, with the fair-value anchors, kill criteria and the $140 trigger all gradeable.

Single biggest risk: the entry, not the business. There is very little wrong with Emerson. There is very little left in the price. At RSI 77.8, 11.3% above its 50-day average, 1.7% from a 52-week high, at the 93rd percentile of its annual range, on the afternoon of the news, with a consensus target 2.2% above the close and a base fair value 5.7% above it — the asymmetry is 1.59:1 on a business guiding approximately 3.5% underlying growth. The good news has been delivered and paid for. The next piece of information is the November order rate, and it is three months away.


Provenance & disclosures